Cognition Therapeutics, Inc. (CGTX) — Financial statements
Income statement, balance sheet, and cash flow for Cognition Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00↓100.0% | 0.24 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00↑100.0% | -0.24 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 37↓10.8% | 42↑12.0% | 37↑22.7% | 30↑63.3% | 19 | |
| General & Administrative Expenses | 11↓13.7% | 12↓9.2% | 14↑2.3% | 13↑31.9% | 10 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 11↓13.7% | 12↓9.2% | 14↑2.3% | 13↑31.9% | 10 | |
| Other Expenses | 0.00 | 0.00 | 0.00↑100.0% | -0.24 | 0.00 | |
| Operating Expenses | 48↓11.4% | 54↑6.4% | 51↑17.1% | 43↑51.5% | 29 | |
| Total Costs & Expenses | 48↓11.4% | 54↑6.4% | 51↑16.5% | 44↑52.3% | 29 | |
| Operating Results | ||||||
| Operating Income | -48↑11.4% | -54↓6.4% | -51↓16.5% | -44↓52.3% | -29 | |
| Depreciation & Amortization | 0.23↓14.3% | 0.27↑5.6% | 0.25↑7.2% | 0.24↑152.7% | 0.09 | |
| EBITDA | -23↑31.0% | -34↓32.0% | -26↓20.7% | -21↓97.0% | -11 | |
| EBIT | -23↑30.8% | -34↓31.8% | -26↓20.6% | -21↓97.4% | -11 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.01↑48.0% | -0.03↓192.6% | 0.03↓99.9% | 22↑34.0% | 17 | |
| Interest Income | 0.00 | 0.00↓100.0% | 0.03↓99.9% | 22↑27.3% | 17 | |
| Interest Expense | 0.01↓48.0% | 0.03 | 0.00↓100.0% | 0.03↓96.9% | 0.89 | |
| Non-Operating Income | -24↓21.5% | -20↑19.8% | -25↓12.5% | -22↓24.8% | -18 | |
| Other Income / Expenses | 24↑21.6% | 20↓19.8% | 25↑12.6% | 22↑31.2% | 17 | |
| Income Before Tax | -23↑30.9% | -34↓31.7% | -26↓20.5% | -21↓82.6% | -12 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00↑100.0% | -22 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -23↑30.9% | -34↓31.7% | -26↓3506.6% | 0.76↑106.5% | -12 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -23↑30.9% | -34↓31.7% | -26↓3506.6% | 0.76↑106.5% | -12 | |
| Bottom-Line Net Income | -23↑30.9% | -34↓31.7% | -26↓20.5% | -21↓31.7% | -16 | |
| EPS (Basic) | -0.32↑62.4% | -0.85↑1.2% | -0.86↓16.2% | -0.74↓1.4% | -0.73 | |
| EPS (Diluted) | -0.32↑62.4% | -0.85↑1.2% | -0.86↓16.2% | -0.74↓1.4% | -0.73 | |
| Weighted Average Shares | 73↑83.2% | 40↑32.5% | 30↑3.4% | 29↑30.4% | 22 | |
| Weighted Average Diluted Shares | 73↑83.2% | 40↑32.3% | 30↑3.6% | 29↑30.4% | 22 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.